miR-124 modulates gefitinib resistance through SNAI2 and STAT3 in non-small cell lung cancer

Abstract

Gefitinib is used as a first-line treatment for advanced non-small cell lung cancer (NSCLC). Unfortunately, most NSCLC patients inevitably develop gefitinib resistance during treatment. In addition to EGFR mutation status, the mechanisms involved are largely unknown. In this study, we showed that miR-124, a tumor suppressor, was significantly down-regulated in gefitinib-resistant NSCLC patients and cell lines compared with gefitinib-sensitive patients and cell lines. In addition, the miR-124 depletion induced gefitinib resistance, and miR-124 overexpression sensitized gefitinib-resistant cells to gefitinib. Mechanistic analysis revealed that miR-124 decreased SNAI2 and STAT3 expression by directly targeting their 3'UTRs and that knocking down SNAI2 or STAT3 partly reversed the gefitinib resistance induced by miR-124 depletion. Our data demonstrate that the miR-124 plays a new critical role in acquired resistance to gefitinib and that the manipulation of miR-124 might provide a therapeutic strategy for reversing acquired gefitinib resistance.

Keywords

miR-124 / non-small cell lung cancer / gefitinib-resistance / SNAI2 / STAT3

References

[1] PaoW, MillerV, ZakowskiM, et al. . EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA, 2004, 101(36): 13306-13311 PMID: 15329413 PMCID: 516528

[2] PaoW, ChmieleckiJ. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer, 2010, 10(11): 760-774 PMID: 20966921 PMCID: 3072803

[3] PaezJG, JannePA, LeeJC, et al. . EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004, 304(5676): 1497-1500 PMID: 15118125

[4] MitsudomiT, KosakaT, EndohH, et al. . Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol, 2005, 23(11): 2513-2520 PMID: 15738541

[5] TanCS, GilliganD, PaceyS. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol, 2015, 16(9): 447-459

[6] CiuleanuT, StelmakhL, CicenasS, et al. . Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol, 2012, 13(3): 300-308 PMID: 22277837

[7] CappuzzoF, CiuleanuT, StelmakhL, et al. . Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol, 2010, 11(6): 521-529 PMID: 20493771

[8] LinY, WangX, JinH. EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. Am J Cancer Res, 2014, 4(5): 411-35 PMID: 25232485 PMCID: 4163608

[9] SequistLV, WaltmanBA, Dias-SantagataD, et al. . Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med, 2011, 3(75): 75ra26 PMID: 21430269 PMCID: 3132801

[10] GadgeelSM, WozniakA. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer. Clin Lung Cancer, 2013, 14(4): 322-332 PMID: 23332287

[11] HaradaD, TakigawaN, OchiN, et al. . JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation. Cancer Sci, 2012, 103(10): 1795-1802 PMID: 22712764

[12] NurwidyaF, TakahashiF, MurakamiA, et al. . Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer. Cancer Res Treat, 2012, 44(3): 151-156 PMID: 23091440 PMCID: 3467417

[13] LinS, GregoryRI. MicroRNA biogenesis pathways in cancer. Nat Rev Cancer, 2015, 15(6): 321-333 PMID: 25998712 PMCID: 4859809

[14] KitamuraK, SeikeM, OkanoT, et al. . MiR-134/487b/ 655 cluster regulates TGF-beta-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells. Mol Cancer Ther, 2014, 13(2): 444-453 PMID: 24258346

[15] IzumchenkoE, ChangX, MichailidiC, et al. . The TGFbeta-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors. Cancer Res, 2014, 74(14): 3995-4005 PMID: 24830724 PMCID: 4122100

[16] LiangYJ, WangQY, ZhouCX, et al. . MiR-124 targets Slug to regulate epithelial-mesenchymal transition and metastasis of breast cancer. Carcinogenesis, 2013, 34(3): 713-722 PMID: 23250910

[17] SunY, AiX, ShenS, et al. . NF-kappaB-mediated miR-124 suppresses metastasis of non-small-cell lung cancer by targeting MYO10. Oncotarget, 2015, 6(10): 8244-8254 PMID: 25749519 PMCID: 4480748

[18] DongP, IhiraK, XiongY, et al. . Reactivation of epigenetically silenced miR-124 reverses the epithelial-to-mesenchymal transition and inhibits invasion in endometrial cancer cells via the direct repression of IQGAP1 expression. Oncotarget, 2016, 7(15): 20260-20270 PMID: 26934121 PMCID: 4991452

[19] LiX, YuZ, LiY, et al. . The tumor suppressor miR-124 inhibits cell proliferation by targeting STAT3 and functions as a prognostic marker for postoperative NSCLC patients. Int J Oncol, 2015, 46(2): 798-808 PMID: 25531908

[20] WangX, LiuY, LiuX, et al. . miR-124 inhibits cell proliferation, migration and invasion by directly targeting SOX9 in lung adenocarcinoma. Oncol Rep, 2016, 35(3): 3115-3121 PMID: 26935152

[21] ZhangM, PiaoL, DattaJ, et al. . miR-124 regulates the epithelial-restricted with serine box/epidermal growth factor receptor signaling axis in head and neck squamous cell carcinoma. Mol Cancer Ther, 2015, 14(10): 2313-2320 PMID: 26227488 PMCID: 4596782

[22] GaoY, FanX, LiW, et al. . miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124. Biochem Biophys Res Commun, 2014, 446(1): 179-186 PMID: 24582749

[23] ChangTH, TsaiMF, SuKY, et al. . Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. Am J Respir Crit Care Med, 2011, 183(8): 1071-1079 PMID: 21037017

[24] LoHW, CaoX, ZhuH, et al. . Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin Cancer Res, 2008, 14(19): 6042-6054 PMID: 18829483 PMCID: 2707832

[25] WuK, ChangQ, LuY, et al. . Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells. Oncotarget, 2013, 4(12): 2430-2438 PMID: 24280348 PMCID: 3926838

[26] RhoJK, ChoiYJ, LeeJK, et al. . Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer, 2009, 63(2): 219-226 PMID: 18599154

[27] HuangL, FuL. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B, 2015, 5(5): 390-401 PMID: 26579470 PMCID: 4629442

[28] LamouilleS, SubramanyamD, BlellochR, et al. . Regulation of epithelial-mesenchymal and mesenchymal-epithelial transitions by microRNAs. Curr Opin Cell Biol, 2013, 25(2): 200-207 PMID: 23434068 PMCID: 4240277

[29] HeL, HeX, LimLP, et al. . A microRNA component of the p53 tumour suppressor network. Nature, 2007, 447(7148): 1130-1134 PMID: 17554337 PMCID: 4590999

[30] GuilS, EstellerM. DNA methylomes, histone codes and miRNAs: tying it all together. Int J Biochem Cell Biol, 2009, 41(1): 87-95 PMID: 18834952

[31] ZuL, XueY, WangJ, et al. . The feedback loop between miR-124 and TGF-beta pathway plays a significant role in non-small cell lung cancer metastasis. Carcinogenesis, 2016, 37(3): 333-343 PMID: 26818357

[32] LuQL, LiuJ, ZhuXL, et al. . Expression of nerve growth factor and hypoxia inducible factor-1a and its correlation with angiogenesis in non-small cell lung cancer. J Huazhong Univ Sci Technolog Med Sci, 2014, 34(3): 356-362

[33] MitsudomiT, YatabeY. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci, 2007, 98(12): 1817-1824 PMID: 17888036

[34] XiongH, HongJ, DuW, et al. . Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition. J Biol Chem, 2012, 287(8): 5819-5832 PMID: 22205702

[35] SaitohM, EndoK, FuruyaS, et al. . STAT3 integrates cooperative Ras and TGF-beta signals that induce Snail expression. Oncogene, 2016, 35(8): 1049-1057 PMID: 25961936